Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2022 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about a specific phenomenon: the unit size of the company's repeatable business escalating. We need to look for management's own words conveying that the deals, orders, contracts, projects, customers, sites, or programs they are landing now are individually bigger, broader, or longer than before for the same offering. Let's scan the transcript. The call covers Q4 2022 results. Management discusses various topics: operational performance, regulatory, capital plan, growth opportunities. They mention customer growth, population migration, hyperscale datacenters and blockchain customers. They mention a blockchain customer in Cheyenne going into service shortly. They also mention renewable generation plans, transmission projects, etc. But the question is specifically about whether management conveys that the individual size of what they land has grown versus their own past. For example, are they signing larger contracts, larger projects, larger customers? They mention "hyperscale datacenters and blockchain customers" as opportunities. They say "We're upbeat about our first blockchain customer in Cheyenne, going into service shortly and other prospects we're developing in the region." That suggests they have a first blockchain customer, but no mention of size escalation. They also mention "population migration" and "customer growth" but that's volume, not unit size. They talk about capital plan: "We rolled our capital plan forward by one year, maintaining our five-year forecast total of $3.5 billion. This translates to a run rate of approximately $700 million per year. We've kept our 2023 capital forecast at approximately $600 million to help strengthen our balance sheet while prudently investing capital to maintain a safe system. Our forecast for 2024 is approximately $800 million, reflecting Ready Wyoming and our intentional deferral of some projects." That's about capital spending, not about deals or contracts. They mention "incremental investment opportunities" like renewable generation, but not that these are larger than past ones.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.